What studies of compounded injections found
A 2025 study reviewed records of 94 people receiving weekly compounded semaglutide with cyanocobalamin, a form of vitamin B12, in a commercial wellness program. Mean weight loss at three months was 4.11 kg, or 4.57% of starting body weight. The study had no control group, so it could not isolate the effects of the medication, B12, or the program. All authors reported salary support from Restore Hyper Wellness [1].
When interpreting claims about adding B12 to semaglutide, keep in mind that every participant received the combination, so the study could not isolate a B12 effect. Absolute lean mass and skeletal muscle mass fell, even though their shares of total weight increased [1].
A separate retrospective study from the Australian Juniper program compared compounded and noncompounded semaglutide with health coaching. Among participants with eligible follow-up weights, mean loss around four months was 9.11% in the compounded group (923 people) and 9.87% in the noncompounded group (1,858). Patients were not randomly assigned. The analysis used available follow-up and was not a trial against Wegovy. Two authors reported salaries from Juniper’s parent company [4].
A 2026 preprint analyzed a matched sample of 3,657 existing Noom users across three programs. At 16 weeks, estimated average weight loss was 8.3% and 9.1% in the two groups prescribed compounded semaglutide and 2.6% in the behavioral program group. Patients chose their programs. The study used observational data, all authors reported working for Noom as employees or contractors, and the preprint had not undergone peer review as of this update [5].
How to read the Wegovy and Mayo results
The Mayo Clinic cohort recorded mean losses of 5.9% at three months among 175 patients and 10.9% at six months among 102. Those figures combine patients who received different semaglutide doses. Only 77 of the 175 reached 1.7 or 2.4 mg[2]. The three- and six-month averages therefore describe groups with different follow-up counts.
The randomized STEP 1 trial enrolled 1,961 adults with overweight or obesity and no diabetes. With lifestyle intervention in both groups, mean weight loss at 68 weeks was 14.9% with weekly semaglutide targeted to 2.4 mg and 2.4% with placebo [3]. The guide to weight loss reported in GLP-1 studies explains why dose, follow-up and patient population matter when comparing these averages.
What FDA policy means for these findings
The FDA does not preapprove compounded semaglutide for safety, quality or effectiveness [6]. The post-shortage compounding rules depend in part on whether a state-licensed pharmacy or an outsourcing facility makes the product. Under section 503A, an exception to FDA’s copy analysis can depend on a prescriber documenting that the compounded change makes a significant difference for a specific patient. FDA says adding B12 can still result in a product it considers essentially a copy. Under section 503B, separate restrictions apply to compounding from bulk substances. FDA’s April 2026 guidance said semaglutide was on neither the 503B bulk substances list nor the drug shortage list[7].
These studies examined injections. If you are reading claims about under-the-tongue semaglutide, the route and formulation need their own evidence. Outcomes from an injection cannot establish how much of an under-the-tongue formulation reaches the bloodstream or what weight loss it produces.